Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology. The therapies in development across our family of companies target a wide range of diseases including uterine fibroids, endometriosis, prostate cancer, Parkinson’s disease, diabetes, pulmonary arterial hypertension, and multiple rare and fatal pediatric conditions. We focus on disease areas where the magnitude of R&D investment from industry is disproportionately low relative to societal medical needs. In addition to our biopharmaceutical subsidiaries, we also build technology-focused Vants focused on improving the process of developing and commercializing medicines.
Looking for a particular Roivant Sciences employee's phone or email?
The Roivant Sciences annual revenue was $122.6 million in 2026.
Matthew Gline is the CEO of Roivant Sciences.
173 people are employed at Roivant Sciences.
Roivant Sciences is based in New York, New York.
The NAICS codes for Roivant Sciences are [325, 3254, 32541, 32].
The SIC codes for Roivant Sciences are [283, 28].